News for Zhaoke Ophthalmology Limited (6622.HK)

Published at

Jun 8, 2023 9:09 PM

by prnewswire.com

positive

positive

Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer™ for the Treatment of Dry Eye Disease

/PRNewswire/ -- Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to...

6622.HK

Read more →
Published at

Nov 1, 2021 2:00 PM

by thestreet.com

mixed

mixed

Sorrento's License Partner, Lee's Pharmaceutical Announces NDA Filing Acceptance By NMPA For Anti-PD-L1 Antibody Socazolimab For Treatment Of Recurrent Or Metastatic Cervical Cancer

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee's Pharma. China National Medical Products

0950.HK SRNE 6622.HK 0L85.L

Read more →
Published at

Aug 19, 2021 6:43 AM

by markets.businessinsider.com

positive

positive

Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint

Largest Ever Completed Dry Eye Disease (DED) clinical trial to date in ChinaZhaoke Ophthalmology's in-house developed innovative drug candidateTar...

6622.HK

Read more →
Published at

Jul 23, 2021 5:37 PM

by thestreet.com

neutral

neutral

Lee's Pharmaceutical Announces First Patient Dosed With Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, As A First-Line Treatment Of Extensive-Stage Small-Cell Lung Cancer

China Oncology Focus, a subsidiary of Lee's Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with

SRNE 6622.HK 0L85.L 0950.HK

Read more →
Published at

May 24, 2021 11:00 AM

by marketscreener.com

positive

positive

Zhaoke Ophthalmology : Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspect

HONG KONG, May 24, 2021 /PRNewswire/ -- Zhaoke Ophthalmology Limited , an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that... | May 24, 2021

6622.HK

Read more →
Published at

May 24, 2021 10:58 AM

by markets.businessinsider.com

positive

positive

Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdon...

HONG KONG, May 24, 2021 /PRNewswire/ -- Zhaoke Ophthalmology Limited ('Zhaoke Ophthalmology' or the 'Company'; stock code: 6622), an ophthalmic ph...

6622.HK

Read more →

News for Zhaoke Ophthalmology Limited (6622.HK)

Zhaoke Ophthalmology Enters into Exclusive License, Supply and Distribution Agreement with Eyedetec Medical to Commercialize Eye Lipid Mobilizer™ for the Treatment of Dry Eye Disease

Sorrento's License Partner, Lee's Pharmaceutical Announces NDA Filing Acceptance By NMPA For Anti-PD-L1 Antibody Socazolimab For Treatment Of Recurrent Or Metastatic Cervical Cancer

Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint

Lee's Pharmaceutical Announces First Patient Dosed With Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, As A First-Line Treatment Of Extensive-Stage Small-Cell Lung Cancer

Zhaoke Ophthalmology : Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspect

Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdon...